Canada Markets open in 2 hrs 10 mins

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0500+0.0500 (+5.00%)
At close: 04:00PM EDT
1.0200 -0.03 (-2.86%)
Pre-Market: 06:29AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.0000
Open1.0400
Bid1.0100 x 2900
Ask1.0500 x 1800
Day's Range1.0200 - 1.0702
52 Week Range0.8400 - 4.3100
Volume1,046,085
Avg. Volume1,376,882
Market Cap132.955M
Beta (5Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

    SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2022, and provides an update on recent company developments. Key developments from Q2 2022 and to date include: Completed dosing in both Part B and Part C (of fo

  • GlobeNewswire

    Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

    Atossa Plans to Initiate a New Development Path in Patients with Compromised Lung-Function Resulting from Cancer TreatmentSEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces it has completed dosing participants in Part C of its Phase 1/2a

  • GlobeNewswire

    Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations

    SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces the appointment of Charles Butler, a 25-year veteran in the healthcare communications space, as vice president of investor relations and public relations. “As Atossa continue